Introduction
follow-up examination at 4 months post-injections, visual acuity had improved to 0.9 and OCT imaging showed regression of the subretinal fluid ( Figure 5 ). Although the patient's vision was stable during that period, a decline in visual acuity was observed 3 months later. An additional intravitreal ranibizumab injection was administered when the visual acuity in the right eye reached 0.4. At final follow-up 2 months after the injection, OCT revealed that the subretinal fluid had regressed, and visual acuity had improved to 0.8. The patient's condition was stable during the 2-year follow-up period and no additional injections were required.
Discussion
The main causes of vision loss in choroidal osteoma are the development of CNV, subfoveal fluid, and photoreceptor degeneration. 5 CNV is seen more frequently among patients exhibiting a combination of hemorrhage and surface irregularities. 5 Shields et al. 3 observed CNV development in 31% of their 61 choroidal osteoma patients, while Aylward et al. 4 reported the incidence as 47% in their study of 36 patients. Although the mechanism by which CNV develops is not well understood, researchers have suggested that retinal pigment epithelium damage CNV in the underlying choroid, or that osteoma itself has neovascular membrane extensions. 1, 7 FFA and OCT are useful methods for identifying CNV.
There is no standard method for the treatment of choroidal osteoma. Patients must be followed regularly and secondary complications must be treated as appropriate. In the management of CNV secondary to choroidal osteoma, partial success has been achieved using thermal laser photocoagulation and photodynamic therapy (PDT) for extrafoveal lesions, and transpupillary thermotherapy and PDT for subfoveal lesions. However, some studies showed that these treatment methods might leading to tumor decalcification, thus increasing retinal damage. 8, 9, 10 It is believed that laser photocoagulation may not have adequate efficacy in cases of CNV secondary to choroidal osteoma due to insufficient tumor melanine and a thinned, degenerated RPE-Bruch's membrane complex.
1 While PDT provides shortterm improvement in visual acuity, it has been demonstrated that retreatment may be necessary and final visual acuity may decline. 11 Surgical removal of subfoveal CNV membranes results in favorable anatomic outcomes, but researchers have reported the procedure unsuccessful in terms of visual acuity. 12 Another method employed in the treatment of these patients is intravitreal anti-vascular endothelial growth factor (anti-VEGF). Bevacizumab and ranibizumab injections have been tested for this purpose, and positive outcomes were reported in both anatomy and visual acuity. 5, 6 It is thought that in choroidal osteoma cases, normal tissues are also damaged during the process, and VEGF expression is increased as a result of choroidal and retinal ischemic stress and chronic inflammation. RPE damage together with thinning of Bruch's membrane and the choriocapillaris may contribute to the development of CNV. Thus, increased VEGF supports abnormal neovascularization. Therefore, anti-VEGF agents may be effective in treatment. 13 The first trials of intravitreal bevacizumab in the literature were conducted for this purpose and yielded favorable results. 6, 13 In a case reported by Ahmadieh and Vafi, 6 visual acuity Bruch's membrane to the subretinal area, thus increasing the drug's efficacy. 6 The first reported use of intravitreal ranibizumab injection for CNV secondary to choroidal osteoma was by Song and Roh 5 in 2009; they found that CNV had regressed and visual acuity had improved from 20/200 to 20/100 at 6 months post-injection. In another case report, Gupta et al.
14 observed CNV regression after ranibizumab injection and no recurrence was detected in 30 months of follow-up. Wu et al. 15 reported a case in which visual acuity improved from 20/800 to 20/30 after 3 injection and no recurrence was observed during 1.2 years of follow-up. Mansour et al. 16 demonstrated in their series consisting of 26 cases that intravitreal ranibizumab and bevacizumab were effective. In our case, visual acuity improved from 0.16 to 0.9 after 3 monthly injections. However, a decrease in visual acuity 3 months after the final injection and CNV recurrence necessitated another ranibizumab injection.
In conclusion, although intravitreal ranibizumab injection is highly beneficial in the treatment of CNV secondary to choroidal osteoma in terms of visual acuity and anatomic recovery, recurrence may be observed, as our case also shows. Therefore, patients should be examined regular at monthly intervals, and treatment should be supported by repeated intravitreal anti-VEGF injections when required.
Ethics

